<DOC>
	<DOCNO>NCT00681811</DOCNO>
	<brief_summary>This multi-center , open-label , extension study patient late infantile MLD previously complete clinical study HGT-MLD-048 ( NCT00633139 ) , define completion Week 52 procedure . This group patient offer ongoing treatment HGT-1111 protocol . One infusion give every week product commercially available , patient discontinues , study terminate Sponsor , provide safety issue emerge .</brief_summary>
	<brief_title>Open-Label Extension Study Recombinant Human Arylsulfatase A ( HGT-1111 ) Late Infantile MLD</brief_title>
	<detailed_description>The primary objective study provide ongoing treatment HGT-1111 patient complete study HGT-MLD-048 ( previously study rhASA-03 - NCT00633139 ) HGT-1111 commercially available study terminate Sponsor , provide safety concern emerge . The secondary objective study monitor disease progression safety profile HGT-1111 administer patient complete study HGT-MLD-048 ( NCT00633139 ) .</detailed_description>
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>1 . Subject 's legally authorize guardian ( ) must provide sign , inform consent prior perform studyrelated activity ( Trialrelated activity procedure would perform normal management subject ) 2 . Completion study HGTMLD048 ( NCT00633139 ) 3 . The subject his/her guardian ( ) must ability comply protocol 1 . Spasticity severe inhibit transportation 2 . Presence know clinically significant cardiovascular , hepatic , pulmonary renal disease medical condition , opinion Investigator , would preclude participation trial 3 . Any medical condition serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Metazyme</keyword>
	<keyword>Late Infantile Metachromatic Leukodystrophy</keyword>
</DOC>